Mitsubishi UFJ Asset Management Co. Ltd. Acquires 15,375 Shares of Elevance Health, Inc. $ELV

Key Points

• Mitsubishi UFJ Asset Management raised its stake in Elevance by 3.4% in Q4, buying 15,375 shares to hold 470,386 shares (about 0.21% of the company) valued at roughly $166.63 million.
• Strong quarterly results: Elevance reported $12.58 EPS vs. $10.74 expected and $49.49 billion in revenue vs. $48.21 billion, with analysts forecasting ~26.79 EPS for the year and a consensus price target of $384.58.
• Dividend announced: Elevance declared a $1.72 quarterly dividend (annualized $6.88, ~1.8% yield), with an ex-dividend date of June 10 and payment on June 25.

Mitsubishi UFJ Asset Management Co. Ltd. grew its stake in shares of Elevance Health, Inc. (NYSE:ELV - Free Report) by 3.4% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 470,386 shares of the company's stock after buying an additional 15,375 shares during the period. Mitsubishi UFJ Asset Management Co. Ltd. owned 0.21% of Elevance Health worth $166,634,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds have also recently modified their holdings of ELV. Physician Wealth Advisors Inc. increased its stake in Elevance Health by 331.6% in the 3rd quarter. Physician Wealth Advisors Inc. now owns 82 shares of the company's stock worth $26,000 after acquiring an additional 63 shares during the last quarter. Activest Wealth Management raised its stake in Elevance Health by 66.7% during the third quarter. Activest Wealth Management now owns 85 shares of the company's stock valued at $27,000 after purchasing an additional 34 shares in the last quarter. Rossby Financial LCC lifted its position in Elevance Health by 110.0% during the third quarter. Rossby Financial LCC now owns 84 shares of the company's stock valued at $28,000 after purchasing an additional 44 shares during the last quarter. ORG Partners LLC increased its holdings in shares of Elevance Health by 120.4% in the 4th quarter. ORG Partners LLC now owns 108 shares of the company's stock worth $38,000 after buying an additional 59 shares during the last quarter. Finally, Loring Wolcott & Coolidge Fiduciary Advisors LLP MA purchased a new stake in shares of Elevance Health during the 4th quarter valued at about $38,000. Hedge funds and other institutional investors own 89.24% of the company's stock.

Elevance Health Price Performance

Shares of ELV stock opened at $374.84 on Thursday. The stock's 50-day moving average is $312.00 and its 200 day moving average is $331.96. Elevance Health, Inc. has a 1-year low of $273.71 and a 1-year high of $424.24. The company has a debt-to-equity ratio of 0.70, a current ratio of 1.48 and a quick ratio of 1.48. The company has a market cap of $81.40 billion, a P/E ratio of 15.94, a PEG ratio of 2.10 and a beta of 0.66.

Elevance Health (NYSE:ELV - Get Free Report) last announced its earnings results on Wednesday, April 22nd. The company reported $12.58 EPS for the quarter, topping analysts' consensus estimates of $10.74 by $1.84. The business had revenue of $49.49 billion during the quarter, compared to the consensus estimate of $48.21 billion. Elevance Health had a net margin of 2.62% and a return on equity of 15.58%. The firm's revenue was up 1.5% on a year-over-year basis. During the same period in the previous year, the company posted $11.97 earnings per share. Elevance Health has set its FY 2026 guidance at 19.850- EPS. Research analysts predict that Elevance Health, Inc. will post 26.79 earnings per share for the current fiscal year.

Elevance Health Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Thursday, June 25th. Investors of record on Wednesday, June 10th will be given a dividend of $1.72 per share. The ex-dividend date of this dividend is Wednesday, June 10th. This represents a $6.88 dividend on an annualized basis and a yield of 1.8%. Elevance Health's dividend payout ratio is presently 29.26%.

Wall Street Analyst Weigh In

A number of equities research analysts have issued reports on the company. The Goldman Sachs Group upped their price objective on Elevance Health from $350.00 to $370.00 and gave the company a "neutral" rating in a research report on Friday, April 24th. UBS Group set a $400.00 price objective on shares of Elevance Health in a research note on Thursday, January 29th. Royal Bank Of Canada lowered shares of Elevance Health from an "outperform" rating to a "sector perform" rating and set a $358.00 target price for the company. in a report on Tuesday, February 3rd. Evercore increased their price objective on shares of Elevance Health from $345.00 to $360.00 in a research report on Thursday, April 23rd. Finally, Bank of America raised Elevance Health from a "neutral" rating to a "buy" rating and upped their target price for the company from $405.00 to $435.00 in a research note on Wednesday, April 29th. Thirteen equities research analysts have rated the stock with a Buy rating and ten have given a Hold rating to the company's stock. Based on data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus target price of $384.58.

About Elevance Health

Elevance Health, Inc NYSE: ELV is a large U.S.-based health benefits company that provides a broad range of health insurance products and related services. Headquartered in Indianapolis, the company rebranded from Anthem, Inc to Elevance Health in 2022 while continuing to operate consumer-facing health plans under established state and national brands. Gail Boudreaux serves as chief executive officer and president, leading the company's strategic focus on integrated health care and benefit delivery.

Elevance's core activities include offering medical and specialty health plans for individuals, employers and government programs, including Medicare and Medicaid managed-care products.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.